111 related articles for article (PubMed ID: 24163974)
1. [Chemotherapy in conjunction with blood brain barrier disruption in the treatment of primary central nervous system lymphoma].
Kuittinen O; Siniluoto T; Isokangas M; Turpeenniemi-Hujanen T; Peltonen J; Alahuhta S; Sonkajärvi E
Duodecim; 2013; 129(15):1563-70. PubMed ID: 24163974
[TBL] [Abstract][Full Text] [Related]
2. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA
Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
[TBL] [Abstract][Full Text] [Related]
3. Real-time monitoring of human blood-brain barrier disruption.
Kiviniemi V; Korhonen V; Kortelainen J; Rytky S; Keinänen T; Tuovinen T; Isokangas M; Sonkajärvi E; Siniluoto T; Nikkinen J; Alahuhta S; Tervonen O; Turpeenniemi-Hujanen T; Myllylä T; Kuittinen O; Voipio J
PLoS One; 2017; 12(3):e0174072. PubMed ID: 28319185
[TBL] [Abstract][Full Text] [Related]
4. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
[TBL] [Abstract][Full Text] [Related]
5. Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
Galor A; Ference SJ; Singh AD; Lee MS; Stevens GH; Perez VL; Peereboom DM
Am J Ophthalmol; 2007 Jul; 144(1):45-49. PubMed ID: 17601426
[TBL] [Abstract][Full Text] [Related]
6. [Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas].
Heimberger K; Samec P; Podreka I; Binder H; Suess E; Reisner T; Deecke L; Steger G; Hiesmayr M; Dittrich C
Wien Klin Wochenschr; 1987 May; 99(11):385-8. PubMed ID: 3113082
[TBL] [Abstract][Full Text] [Related]
7. Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption.
Vicuna-Kojchen J; Frenkel S; Siegal T; Shalom E; Chowers I; Pe'er J
Br J Ophthalmol; 2008 Feb; 92(2):231-5. PubMed ID: 18227203
[TBL] [Abstract][Full Text] [Related]
8. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival.
Kraemer DF; Fortin D; Doolittle ND; Neuwelt EA
Neurosurgery; 2001 May; 48(5):1033-40; discussion 1040-1. PubMed ID: 11334269
[TBL] [Abstract][Full Text] [Related]
9. Re: Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
Goldstein DA; Tessler HH
Am J Ophthalmol; 2007 Dec; 144(6):976; author reply 976. PubMed ID: 18036877
[No Abstract] [Full Text] [Related]
10. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.
McAllister LD; Doolittle ND; Guastadisegni PE; Kraemer DF; Lacy CA; Crossen JR; Neuwelt EA
Neurosurgery; 2000 Jan; 46(1):51-60; discussion 60-1. PubMed ID: 10626935
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
12. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
Jahnke K; Kraemer DF; Knight KR; Fortin D; Bell S; Doolittle ND; Muldoon LL; Neuwelt EA
Cancer; 2008 Feb; 112(3):581-8. PubMed ID: 18072268
[TBL] [Abstract][Full Text] [Related]
13. New treatment approaches in primary central nervous system lymphoma.
Soussain C; Hoang-Xuan K; Doolittle ND
Hematol Oncol Clin North Am; 2005 Aug; 19(4):719-28, vii. PubMed ID: 16083832
[TBL] [Abstract][Full Text] [Related]
14. Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances.
Doolittle ND; Muldoon LL; Culp AY; Neuwelt EA
Adv Pharmacol; 2014; 71():203-43. PubMed ID: 25307218
[TBL] [Abstract][Full Text] [Related]
15. Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy.
Dahlborg SA; Henner WD; Crossen JR; Tableman CM; Petrillo A; Braziel R; Neuwelt EA
Cancer J Sci Am; 1996; 2(3):166-74. PubMed ID: 9166517
[TBL] [Abstract][Full Text] [Related]
16. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans.
Siegal T; Rubinstein R; Bokstein F; Schwartz A; Lossos A; Shalom E; Chisin R; Gomori JM
J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648
[TBL] [Abstract][Full Text] [Related]
17. Serum S-100beta as a possible marker of blood-brain barrier disruption.
Kapural M; Krizanac-Bengez Lj; Barnett G; Perl J; Masaryk T; Apollo D; Rasmussen P; Mayberg MR; Janigro D
Brain Res; 2002 Jun; 940(1-2):102-4. PubMed ID: 12020881
[TBL] [Abstract][Full Text] [Related]
18. Blood-brain barrier disruption for the treatment of malignant brain tumors: The National Program.
Doolittle ND; Petrillo A; Bell S; Cummings P; Eriksen S
J Neurosci Nurs; 1998 Apr; 30(2):81-90. PubMed ID: 9642616
[TBL] [Abstract][Full Text] [Related]
19. Primary central nervous system lymphoma: biological aspects and controversies in management.
Bessell EM; Hoang-Xuan K; Ferreri AJ; Reni M
Eur J Cancer; 2007 May; 43(7):1141-52. PubMed ID: 17433666
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors and Disease Course for Blood-Brain Barrier Disruption-Associated Maculopathy.
Simonett JM; Skalet AH; Lujan BJ; Neuwelt EA; Ambady P; Lin P
JAMA Ophthalmol; 2021 Feb; 139(2):143-149. PubMed ID: 33270081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
